Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ISTp-US-Py vs IPTp-SP for Malaria Prevention in Pregnancy (ULTRAPYRAPREG)
NCT04783051Phase 3Completed
- Sponsor
- Université de Kinshasa
- Start
- May 2021
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pyronaridine in malaria (2 arms), sponsored by Université de Kinshasa. Primary endpoints: Proportion of asymptomatic malaria at 6 months, Proportion of symptomatic malaria at 6 months and 5 more. Started May 2021; status: completed.
02
Drugs
pyronaridine
03
Conditions
malaria
Beyond the preview
Go deeper on NCT04783051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04783051.